Jeffrey Infante, MD

Jeffrey Infante, MD, Director of Drug Development at Sarah Cannon, discusses findings of the AM0010 study.

Jeffrey Infante, MD, director, Drug Development Program, Sarah Cannon Research Institute, discusses a phase Ib, open-label expansion trial examining avelumab for the treatment of patients with previously treated, recurrent or refractory ovarian cancer.